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costs associated with the treatment of IBS in England. Methods: Hospital Episode 
Statistics (HES) data for 2012-13 for all clinical commissioning groups (CCGs) in 
England were analysed to calculate the tariff cost of IBS. IBS diagnosis codes were 
included in the analysis. Prescribing data and cost (PACT) data for 2012-13 were 
also analysed. Results: During 2012/13 there were 1,217,993 outpatient appoint-
ments in gastroenterology and colorectal surgery specialities, with a total tariff cost 
of £365,868,937. Despite this, only 1,982 patients were recorded with IBS-specific 
codes, with a total estimated tariff cost of £812,336. In addition, 28,849 patients 
were recorded with IBS-related symptom codes at a cost of £11,002,874. There were 
also 658,698 diagnostic lower GI endoscopies at a tariff cost of £169,676,704. Of 
these, 323,752 (49%) had no further follow-up in secondary care in the subsequent 
12 months. PACT data indicated that £44,977,959 and £25,582,752 was spent on 
selected laxatives and antispasmodics, respectively, commonly used to treat IBS in 
primary care. ConClusions: Despite being poorly clinically coded, it is clear that 
IBS places a significant cost burden on the NHS. Notably, 49% of patients seen for 
lower GI endoscopies had no further activity provided by the Hospital Provider Trust 
as an inpatient or outpatient over the subsequent 12 months, implying functional 
symptoms. Better diagnosis and subsequent management of IBS within a primary 
care setting may provide direct savings in the cost of IBS management. This study 
was financially supported by Almirall. Hospital Episode Statistics Data were pro-
vided via Harvey Walsh Ltd under commercial reuse licence.
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objeCtives: There are an estimated 620,000 patients with inflammatory bowel 
disease (IBD) in the UK. The rising incidence of IBD combined with its incurability 
has significant cost implications, with the National IBD Audit estimating that cost 
to the National Health Service (NHS) exceeded £1 billion in 2010. The aim of this 
cost of care model was to calculate the annual cost per patient of treating ulcerative 
colitis (UC) and Crohn’s disease (CD) from an NHS perspective, and to enable areas 
of potential cost savings to be explored. Methods: The cost of IBD was calculated 
by summing the costs of treatment, treatment side effects and disease-related com-
plications, accounting for the proportions of patients incurring these costs. The 
model included detailed costs for each treatment (eg. brand of mesalazine), major 
side effects for each treatment (eg. pancreatitis from thiopurines) and complica-
tions (eg. pyoderma gangrenosum). Default input values for costs, the percentage 
of patients receiving each treatment, and the percentage of patients experiencing 
side effects or complications were determined from national sources and published 
literature. However, the model permitted the user to input local or alternative data 
(eg. to reflect brand preferences for oral mesalazines) and conduct scenario analy-
ses. Results: Using default input values, the annual cost of treating any UC patient 
was estimated to be £3,084. For a UC patient in remission, in relapse with mild-to-
moderate UC or in relapse with severe UC, annual cost per patient was estimated 
to be £1,693, £2,903 and £10,760, respectively. The annual cost for any CD patient 
was estimated to be £6,156 (£1,800 for patients in remission; £10,513 for patients in 
relapse). ConClusions: IBD is a costly, chronic condition and this model facilitates 
calculation of annual costs per UC and CD patient. The models’ customisability will 
help hospitals to identify areas where savings could be made.
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objeCtives: To estimate health care resource use and costs associated with the man-
agement and treatment of constipation predominant irritable bowel syndrome (IBS-C) 
in Spanish clinical practice. Methods: The 2011 primary care (PC) IASIST database, 
which includes 3,678,522 clinical charts corresponding to PC sites from the National 
Health System (NHS), was used to estimate the number of patients with IBS-C (identi-
fied by a combination of ICD code and prescription of IBS-C drugs) and obtain data 
on the number of hospitalizations (service, frequency and duration), scheduled and 
emergency visits to PC, referrals to specialist care, and IBS-C treatments prescribed 
and dispensed in retail pharmacies and their associated costs. Based on data from 
IASIST database and unit costs retrieved from the e-Salud database, health care costs 
associated with IBS-C from the NHS perspective were calculated. Results: A total of 
5,649 IBS-C patients were indentified in the database, corresponding to a prevalence 
of 0.15% of patients attending PC. Total costs associated with IBS-C in the sample were 
estimated to be € 4,755,725; highest costs were associated with PC visits (€ 2,791,725, 
corresponding to 58.7% of total IBS-C costs). This high cost of PC visits is explained by 
the high number of visits by IBS-C patients (17.4 visits annually per patient). Costs of 
PC visits are followed by hospitalization costs (€ 610,859, 12.8% of total cost), medical 
visits to specialists (€ 556,164, 11.7%) and emergency room visits to PC (€ 491,142,10.3%). 
Costs of pharmacological treatment (€ 305,707) represented only 6.4% of total IBS-C 
costs. ConClusions: The low prevalence of IBS-C observed may be due to the under-
registration or under-diagnosis of IBS-C. Costs associated with the management of 
IBS-C are driven mainly by the high number of PC visits, which may be associated 
with the current unmet medical needs in IBS-C.
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from $1,747 to $48,782 per patient year. Per patient episode, direct costs associated 
with OIC ranged from $54 to $11,705. This was further supported by a large inter-
national study which reported significantly more physician visits and alternative 
care provider visits among patients with OIC than those without OIC. Two studies 
reported on a subgroup of patients with OIC who failed to respond to laxatives; 
these patients reported higher direct costs than patients who had a response to 
laxatives. ConClusions: The management of OIC is associated with potentially 
significant health care resource utilisation and financial burden. Patients with OIC 
incur higher direct health care costs than those without OIC and costs are increased 
further if patients with OIC have failed to respond to laxatives. There remains a 
paucity of data on health care resource utilisation in OIC and further research into 
the economic burden of OIC is needed.
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objeCtives: This study is the first study to assess the burden of IBS-C in 6 European 
countries (France, Germany, Italy, Spain, Sweden, UK). Here we present the results 
for Spain. Methods: Observational, retrospective-prospective (6 months each) 
study in patients diagnosed with moderate-to-severe IBS-C in the last five years 
(Rome-III criteria). Moderate-to-severe IBS-C was defined as IBS-Symptom Severity 
Score (IBS-SSS) ≥ 175. Quality-of-life (QoL) was assessed with EuroQoL-5D (EQ-5D) 
and IBS-QoL. Results: 112 patients were included (58% severe, mean age (±SD) 
46.8±13.7 years, 86% female). At baseline, symptom severity (IBS-SSS; severe > 300) 
was 315.4±82.9; presenteeism (WPA: IBS-C questionnaire; mean [±SD] % time in 
week prior to inclusion): 32.3±27.2; absenteeism: 6.1±15.8; work productivity loss: 
29.2±27.5; and daily activity impairment 39.6±27.2. Mean IBS-QoL was 41.0±21.2, 
(scale: 0-100 [best-to-worst]), and the most affected domains were “food avoidance” 
(mean: 60.4) and “health worry” (54.6). Mean EQ-5D was 57±21 (scale: 0-100 [worst-
to-best]) and 86% and 63% of patients reported moderate-to-severe problems in 
pain/discomfort, anxiety/depression respectively. The most prevalent symptoms 
were: constipation (84%), abdominal pain (80%), abdominal distention (80%) and 
bloating (59%). Over the year, 88% of patients consulted a primary care physician, 
and 82% a gastroenterologist; mean (95%CI): 3.8 and 2.3 visits, respectively. 20% of 
patients required emergency department visits or hospitalization (mean stay: 1.5 
(0.6-2.4) days). 58% of patients underwent a diagnostic test (mean: 2.4 (1.8-2.9)). 
85% of patients took pharmacological medication (80% took some pharmacological 
medication for their IBS-C) 30% received complementary therapies. After 6 months 
of follow-up, only 1 in 5 patients had no or mild symptoms. The mean (95%CI) annual 
direct cost for the Spanish National Health System (NHS) was 1067€ (730-1447) and 
the mean cost for the patient was 568€ (333-841). 13% of patients took sick leave 
(mean: 6.3 times; mean duration: 52 days) and 28% had productivity losses (mean: 
55 hours). Mean indirect costs were 1362€ (313-2866). Total costs amounted to 2997€ 
(1799-4515) /year. ConClusions: Moderate-to-severe IBS-C has a great impact on 
patient QoL, productivity, and health care resource utilization.
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objeCtives: The burden and cost of liver disease is known to be substantial, but accu-
rate data on this subject is still scarce in Portugal. So far most estimates are obtained 
from diagnosis-related groups (DRGs) associated with hospital financing and from 
expert panels. In this analysis we aimed to calculate the real costs associated with 
hospital admissions due to liver cirrhosis (LC) in a large hospital. Methods: All hos-
pitalizations in the gastroenterology department from a tertiary hospital in Portugal 
(Centro Hospitalar Lisboa Central) during 2012 were analyzed. Patient level data was 
used to retrieve relevant demographic and clinical information. Costs assumed to be 
specific for LC admissions, namely medication, imaging and other techniques, were 
estimated directly. Department-specific hospital accountancy was used to include 
the remaining hospital costs associated with these hospitalizations. Results: A 
total of 644 admissions were analyzed, from which 135 (21.0%) were due to LC, cor-
responding to 82 patients. 74.4% (n= 61) were males, median age was 55 years. The 
main cause of LC was alcohol (58.5%). In the admissions due to LC, average length 
of stay (LoS) was 15.3 days and total mean hospitalization cost was 3,979.5€ . For all 
analyzed admissions, average LoS and mean total cost were 8.1 days and 2,323.8€ , 
respectively. Average cost for medications in admissions for LC amounted to 492.7€ , 
compared to 228.7€ for all admissions. Within admissions for LC, costs were not 
significantly different for hospitalizations with or without hepatocellular carci-
noma. ConClusions: The estimated overall cost of a hospital admission for LC in 
a gastroenterology department was superior to the average value of hospitalizations 
for all causes, and approximately twice the official DRG value. This study highlights 
the current economic burden of liver cirrhosis faced by a tertiary hospital and the pos-
sible need to revise some of the assumptions used for financing Portuguese hospitals.
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objeCtives: The NHS is faced with increasing cost pressures that make the effi-
cient use of resources paramount. Patients with IBS may consume considerable 
NHS resource through inpatient and outpatient visits, diagnostic tests and treat-
ment. This study aimed to estimate admission costs and primary care prescribing 
